Лекарственные средства для лечения атеросклероза: проблемы и перспективы, связанные с их разработкой

  • Елена Ивановна Леонова
  • Оксана Валериановна Галзитская


Одним из самых распространенных заболеваний цивилизованных стран является атеросклероз, при котором в стенках крупных и средних артерий образуются атеросклеротические бляшки. При разрастании таких бляшек происходит постепенное сужение просвета сосудов, сопровождающееся хроническим нарушением кровоснабжения органов. Несмотря на интенсивные исследования в этой области, до сих пор ученым не удалось создать эффективное лекарственное средство, способное победить хроническую патологию. В данном обзоре собран материал, который отражает современное понимание процессов развития атеросклероза и сложности, связанные с его лечением и профилактикой.


Abedin, M., Tintut, Y., and Demer, L.L. (2004). Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. 24, 1161–1170.
Alfon, J., Pueyo Palazon, C., Royo, T., and Badimon, L. (1999). Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb. Haemost. 81, 822–827.
Bäck, M., and Hansson, G.K. (2006). Leukotriene receptors in atherosclerosis. Ann. Med. 38, 493–502.
Bäck, M., and Hansson, G.K. (2015). Anti-inflammatory therapies for atherosclerosis. Nat. Rev. Cardiol. 12, 199–211.
Back, M., Yin, L., and Ingelsson, E. (2012). Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 33, 1928–1933.
Baggio, G., Donazzan, S., Monti, D., Mari, D., Martini, S., Gabelli, C., Dalla Vestra, M., Previato, L., Guido, M., Pigozzo, S., et al. (1998). Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 12, 433–437.
Balarini, C.M., Leal, M.A., Gomes, I.B.S., Pereira, T.M.C., Gava, A.L., Meyrelles, S.S., and Vasquez, E.C. (2013). Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J. Transl. Med. 11, 3.
Bentley, J.K., and Beavo, J.A. (1992). Regulation and function of cyclic nucleotides. Curr. Opin. Cell Biol. 4, 233–240.
van den Berg, B.M., Spaan, J.A.E., Rolf, T.M., and Vink, H. (2006). Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am. J. Physiol. Heart Circ. Physiol. 290, H915-920.
Bilhartz, L.E., Spady, D.K., and Dietschy, J.M. (1989). Inappropriate hepatic cholesterol synthesis expands the cellular pool of sterol available for recruitment by bile acids in the rat. J. Clin. Invest. 84, 1181–1187.
Bousser, M.-G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K.M., Hennerici, M.G., Mattle, H.P., Rothwell, P.M., de Cordoüe, A., et al. (2011). Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet Lond. Engl. 377, 2013–2022.
Brandl, C., Ozgor, L., Wohner, M., Shock, A., and Nitschke, L. (2014). AB0023 In Vivo Effects of Epratuzumab, A Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-In (HUKI) Mice. Ann. Rheum. Dis. 73, 811–811.
Bulgarelli, A., Martins Dias, A.A., Caramelli, B., and Maranhão, R.C. (2012). Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J. Cardiovasc. Pharmacol. 59, 308–314.
Burnett, J.R., Wilcox, L.J., Telford, D.E., Kleinstiver, S.J., Barrett, P.H.R., Newton, R.S., and Huff, M.W. (1999). The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs 1. Endocrinology 140, 5293–5302.
Capra, V., Bäck, M., Angiolillo, D.J., Cattaneo, M., and Sakariassen, K.S. (2014). Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J. Thromb. Haemost. JTH 12, 126–137.
Chan, J.C.Y., Piper, D.E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009). A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. 106, 9820–9825.
Charo, I.F., and Taub, R. (2011). Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat. Rev. Drug Discov. 10, 365–376.
Cheriyan, J., Webb, A.J., Sarov-Blat, L., Elkhawad, M., Wallace, S.M.L., Mäki-Petäjä, K.M., Collier, D.J., Morgan, J., Fang, Z., Willette, R.N., et al. (2011). Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123, 515–523.
Chong, G., and Tebbutt, N.C. (2010). Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther. Adv. Med. Oncol. 2, 309–317.
Collaboration, A.T. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86.
Conde, K., Vergara-Jimenez, M., Krause, B.R., Newton, R.S., and Fernandez, M.L. (1996). Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J. Lipid Res. 37, 2372–2382.
Coomes, E., Chan, E.S.L., and Reiss, A.B. (2011). Methotrexate in Atherogenesis and Cholesterol Metabolism. Cholesterol 2011, 1–8.
Cuchel, M., Bruckert, E., Ginsberg, H.N., Raal, F.J., Santos, R.D., Hegele, R.A., Kuivenhoven, J.A., Nordestgaard, B.G., Descamps, O.S., Steinhagen-Thiessen, E., et al. (2014). Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 35, 2146–2157.
Cutolo, M., Sulli, A., Pizzorni, C., Seriolo, B., and Straub, R.H. (2001). Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60, 729–735.
Cyrus, T., Sung, S., Zhao, L., Funk, C.D., Tang, S., and Praticò, D. (2002). Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106, 1282–1287.
Dabagh, M., Jalali, P., and Tarbell, J.M. (2009). The transport of LDL across the deformable arterial wall: the effect of endothelial cell turnover and intimal deformation under hypertension. AJP Heart Circ. Physiol. 297, H983–H996.
Dai, Y., and Ge, J. (2012). Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease. Thrombosis 2012, 1–7.
Davenport, P., and Tipping, P.G. (2003). The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163, 1117–1125.
Davis, H.R., Compton, D.S., Hoos, L., and Tetzloff, G. (2001a). Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 21, 2032–2038.
Davis, H.R., Pula, K.K., Alton, K.B., Burrier, R.E., and Watkins, R.W. (2001b). The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism. 50, 1234–1241.
Deshmane, S.L., Kremlev, S., Amini, S., and Sawaya, B.E. (2009). Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. J. Interferon Cytokine Res. 29, 313–326.
Deyoung, L., Chung, E., Kovac, J.R., Romano, W., and Brock, G.B. (2012). Daily Use of Sildenafil Improves Endothelial Function in Men With Type 2 Diabetes. J. Androl. 33, 176–180.
Di Marco, E., Gray, S.P., Chew, P., Koulis, C., Ziegler, A., Szyndralewiez, C., Touyz, R.M., Schmidt, H.H.H.W., Cooper, M.E., Slattery, R., et al. (2014). Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice. Diabetologia 57, 633–642.
Doggrell, S.A. (2012). The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opin. Pharmacother. 13, 1469–1480.
Doring, Y., Noels, H., Mandl, M., Kramp, B., Neideck, C., Lievens, D., Drechsler, M., Megens, R.T.A., Tilstam, P.V., Langer, M., et al. (2014). Deficiency of the Sialyltransferase St3Gal4 Reduces Ccl5-Mediated Myeloid Cell Recruitment and Arrest: Short Communication. Circ. Res. 114, 976–981.
Douglas, J.S. (2005). Coronary Stent Restenosis in Patients Treated With Cilostazol. Circulation 112, 2826–2832.
Drinane, M., Mollmark, J., Zagorchev, L., Moodie, K., Sun, B., Hall, A., Shipman, S., Morganelli, P., Simons, M., and Mulligan-Kehoe, M.J. (2009). The Antiangiogenic Activity of rPAI-123 Inhibits Vasa Vasorum and Growth of Atherosclerotic Plaque. Circ. Res. 104, 337–345.
Dzeshka, M.S., Shantsila, A., and Lip, G.Y.H. (2016). Effects of Aspirin on Endothelial Function and Hypertension. Curr. Hypertens. Rep. 18.
Emeson, E.E., and Shen, M.L. (1993). Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am. J. Pathol. 142, 1906–1915.
Everett, B.M., Smith, R.J., and Hiatt, W.R. (2015). Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs. N. Engl. J. Med. 373, 1588–1591.
Feig, J.E., Shang, Y., Rotllan, N., Vengrenyuk, Y., Wu, C., Shamir, R., Torra, I.P., Fernandez-Hernando, C., Fisher, E.A., and Garabedian, M.J. (2011). Statins Promote the Regression of Atherosclerosis via Activation of the CCR7-Dependent Emigration Pathway in Macrophages. PLoS ONE 6, e28534.
Ferri, N., and Corsini, A. (2014). [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk]. G. Ital. Cardiol. 2006 15, 664–669.
Gadioli, A.L.N., Nogueira, B.V., Arruda, R.M.P., Pereira, R.B., Meyrelles, S.S., Arruda, J.A., and Vasquez, E.C. (2009). Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice. Braz. J. Med. Biol. Res. 42, 1191–1195.
de Gaetano, G., and Collaborative Group of the Primary Prevention Project (2001). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet Lond. Engl. 357, 89–95.
Gordon, T., and Kannel, W.B. (1972). Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA 221, 661–666.
Graham, D.J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., and Ray, W.A. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet Lond. Engl. 365, 475–481.
Gram, H. (2016). Preclinical characterization and clinical development of ILARIS® (canakinumab) for the treatment of autoinflammatory diseases. Curr. Opin. Chem. Biol. 32, 1–9.
Grant, B.W., Jung, S.-H., Johnson, J.L., Kostakoglu, L., Hsi, E., Byrd, J.C., Jones, J., Leonard, J.P., Martin, S.E., and Cheson, B.D. (2013). A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119, 3797–3804.
Grimaldi-Bensouda, L., Alpérovitch, A., Aubrun, E., Danchin, N., Rossignol, M., Abenhaim, L., Richette, P., and PGRx MI Group (2015). Impact of allopurinol on risk of myocardial infarction. Ann. Rheum. Dis. 74, 836–842.
Grundy, S.M. (1998). Statin Trials and Goals of Cholesterol-Lowering Therapy. Circulation 97, 1436–1439.
Guimarães, A.C., Malachias, M.V.B., Coelho, O.R., Zilli, E.C., and Luna, R.L. (1999). Use of sildenafil in patients with cardiovascular disease. Arq. Bras. Cardiol. 73, 521–526.
Haag, M.D.M., Bos, M.J., Hofman, A., Koudstaal, P.J., Breteler, M.M.B., and Stricker, B.H.C. (2008). Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch. Intern. Med. 168, 1219–1224.
Hakonarson, H., Thorvaldsson, S., Helgadottir, A., Gudbjartsson, D., Zink, F., Andresdottir, M., Manolescu, A., Arnar, D.O., Andersen, K., Sigurdsson, A., et al. (2005). Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293, 2245–2256.
Hallbergson, A., Esch, J.J., Tran, T.X., Lock, J.E., and Marshall, A.C. (2015a). Systemic rapamycin to prevent in-stent stenosis in peripheral pulmonary arterial disease: early clinical experience. Cardiol. Young 1–8.
Hallbergson, A., Esch, J.J., Tran, T.X., Lock, J.E., and Marshall, A.C. (2015b). Systemic rapamycin to prevent in-stent stenosis in peripheral pulmonary arterial disease: early clinical experience. Cardiol. Young 1–8.
Hansson, G.K., Hellstrand, M., Rymo, L., Rubbia, L., and Gabbiani, G. (1989). Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170, 1595–1608.
Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K.H., Wedel, H., and Westerling, S. (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet Lond. Engl. 351, 1755–1762.
van Heek, M., Farley, C., Compton, D.S., Hoos, L., and Davis, H.R. (2001b). Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol. 134, 409–417.
van Heek, M., Compton, D.S., and Davis, H.R. (2001a). The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. 415, 79–84.
Hennerici, M.G., Bots, M.L., Ford, I., Laurent, S., and Touboul, P.J. (2010). Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial. Cardiovasc. Drugs Ther. 24, 175–180.
Herman, R.H., Cohn, R.M., and McNamara, P.D. (1980). Principles of Metabolic Control in Mammalian Systems.
Hippisley-Cox, J., and Coupland, C. (2005). Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330, 1366.
Holmes, D.R. (2004). Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis. Circulation 109, 634–640.
van der Hoorn, J.W., Jukema, J.W., Bekkers, M.E., Princen, H.M., Corda, S., Emeis, J.J., and Steendijk, P. (2008). Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Crit. Care Med. 36, 2576–2582.
Hoving, S., Heeneman, S., Gijbels, M.J.J., te Poele, J.A.M., Bolla, M., Pol, J.F.C., Simons, M.Y., Russell, N.S., Daemen, M.J., and Stewart, F.A. (2010). NO-Donating Aspirin and Aspirin Partially Inhibit Age-Related Atherosclerosis but Not Radiation-Induced Atherosclerosis in ApoE Null Mice. PLoS ONE 5, e12874.
Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Murata, M., Yokoyama, K., et al. (2014). Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312, 2510–2520.
Jawień, J., Gajda, M., Olszanecki, R., and Korbut, R. (2007). BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 58, 583–588.
Jonasson, L., Holm, J., Skalli, O., Gabbiani, G., and Hansson, G.K. (1985). Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76, 125–131.
Jonasson, L., Holm, J., and Hansson, G.K. (1988). Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl. Acad. Sci. U. S. A. 85, 2303–2306.
Judkins, C.P., Diep, H., Broughton, B.R.S., Mast, A.E., Hooker, E.U., Miller, A.A., Selemidis, S., Dusting, G.J., Sobey, C.G., and Drummond, G.R. (2010). Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am. J. Physiol. Heart Circ. Physiol. 298, H24-32.
Karas, S.P., Gravanis, M.B., Santoian, E.C., Robinson, K.A., Anderberg, K.A., and King, S.B. (1992). Coronary intimal proliferation after balloon injury and stenting in swing: An animal model of restenosis. J. Am. Coll. Cardiol. 20, 467–474.
Kawabe, J., and Hasebe, N. (2014). Role of the Vasa Vasorum and Vascular Resident Stem Cells in Atherosclerosis. BioMed Res. Int. 2014, 1–8.
Kirii, H. (2003). Lack of Interleukin-1beta Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice. Arterioscler. Thromb. Vasc. Biol. 23, 656–660.
Koster, J.K., Tryka, A.F., H’Doubler, P., and Collins, J.J. (1981). The effect of low-dose aspirin and dipyridamole upon atherosclerosis in the rabbit. Artery 9, 405–413.
Kraus, S., Naumov, I., Shapira, S., Kazanov, D., Aroch, I., Afek, A., Eisenberg, O., George, J., Arber, N., and Finkelstein, A. (2014). Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. Isr. Med. Assoc. J. IMAJ 16, 233–238.
Kushiyama, A., Okubo, H., Sakoda, H., Kikuchi, T., Fujishiro, M., Sato, H., Kushiyama, S., Iwashita, M., Nishimura, F., Fukushima, T., et al. (2012). Xanthine Oxidoreductase Is Involved in Macrophage Foam Cell Formation and Atherosclerosis Development. Arterioscler. Thromb. Vasc. Biol. 32, 291–298.
Lee, T.S., Yen, H.C., Pan, C.C., and Chau, L.Y. (1999). The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19, 734–742.
Ley, K., and Huo, Y. (2001). VCAM-1 is critical in atherosclerosis. J. Clin. Invest. 107, 1209–1210.
Liao, J.K., and Laufs, U. (2005). PLEIOTROPIC EFFECTS OF STATINS. Annu. Rev. Pharmacol. Toxicol. 45, 89–118.
Libby, P. (2008). Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J. Lipid Res. 50, S352–S357.
Libby, P., Ridker, P.M., and Hansson, G.K. (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325.
Lin, H.-L., Yen, H.-W., Hsieh, S.-L., An, L.-M., and Shen, K.-P. (2014). Low-dose aspirin ameliorated hyperlipidemia, adhesion molecule, and chemokine production induced by high-fat diet in Sprague-Dawley rats. Drug Dev. Res. 75, 97–106.
Lonn, E., Bosch, J., Yusuf, S., Sheridan, P., Pogue, J., Arnold, J.M.O., Ross, C., Arnold, A., Sleight, P., Probstfield, J., et al. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293, 1338–1347.
Luo, W., Wang, H., Ohman, M.K., Guo, C., Shi, K., Wang, J., and Eitzman, D.T. (2012). P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 220, 110–117.
Lütjohann, D., Stroick, M., Bertsch, T., Kühl, S., Lindenthal, B., Thelen, K., Andersson, U., Björkhem, I., Bergmann Kv, K. von, and Fassbender, K. (2004). High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69, 431–438.
Manka, D., Collins, R.G., Ley, K., Beaudet, A.L., and Sarembock, I.J. (2001). Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 103, 1000–1005.
Marek, Z., Jaegermann, K., and Ciba, T. (1962). Atherosclerosis and levels of serum cholesterol in postmortem investigations. Am. Heart J. 63, 768–774.
Marks, A.R. (2003). Sirolimus for the prevention of in-stent restenosis in a coronary artery. N. Engl. J. Med. 349, 1307–1309.
Martínez, G.J., Robertson, S., Barraclough, J., Xia, Q., Mallat, Z., Bursill, C., Celermajer, D.S., and Patel, S. (2015). Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J. Am. Heart Assoc. 4, e002128.
Maxwell, K.N., and Breslow, J.L. (2004). Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U. S. A. 101, 7100–7105.
Mollmark, J.I., Park, A.J.-H., Kim, J., Wang, T.Z., Katzenell, S., Shipman, S.L., Zagorchev, L.G., Simons, M., and Mulligan-Kehoe, M.J. (2012). Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 32, 2644–2651.
Myant, N.B. (1981). The biology of cholesterol and related steroids (London: Heinemann Medical Books).
Nagy, E., Andersson, D.C., Caidahl, K., Eriksson, M.J., Eriksson, P., Franco-Cereceda, A., Hansson, G.K., and Bäck, M. (2011). Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123, 1316–1325.
Naoum, J.J., Woodside, K.J., Zhang, S., Rychahou, P.G., and Hunter, G.C. (2005). Effects of Rapamycin on the Arterial Inflammatory Response in Atherosclerotic Plaques in Apo-E Knockout Mice. Transplant. Proc. 37, 1880–1884.
Napoli, C., Cirino, G., Del Soldato, P., Sorrentino, R., Sica, V., Condorelli, M., Pinto, A., and Ignarro, L.J. (2001). Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. 98, 2860–2864.
Nicholls, S.J., Kastelein, J.J.P., Schwartz, G.G., Bash, D., Rosenson, R.S., Cavender, M.A., Brennan, D.M., Koenig, W., Jukema, J.W., Nambi, V., et al. (2014). Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial. JAMA 311, 252.
Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A., and Thompson, P.L. (2013). Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. J. Am. Coll. Cardiol. 61, 404–410.
Noble, M.I.M., Drake-Holland, A.J., and Vink, H. (2008). Hypothesis: arterial glycocalyx dysfunction is the first step in the atherothrombotic process. QJM Mon. J. Assoc. Physicians 101, 513–518.
O’Donoghue, M.L., Glaser, R., Cavender, M.A., Aylward, P.E., Bonaca, M.P., Budaj, A., Davies, R.Y., Dellborg, M., Fox, K.A.A., Gutierrez, J.A.T., et al. (2016). Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA 315, 1591.
Oörni, K., Pentikäinen, M.O., Ala-Korpela, M., and Kovanen, P.T. (2000). Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J. Lipid Res. 41, 1703–1714.
Ottani, F., Latini, R., Staszewsky, L., La Vecchia, L., Locuratolo, N., Sicuro, M., Masson, S., Barlera, S., Milani, V., Lombardi, M., et al. (2016). Cyclosporine A in Reperfused Myocardial Infarction. J. Am. Coll. Cardiol. 67, 365–374.
Paramel Varghese, G., Folkersen, L., Strawbridge, R.J., Halvorsen, B., Yndestad, A., Ranheim, T., Krohg‐Sørensen, K., Skjelland, M., Espevik, T., Aukrust, P., et al. (2016). NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis. J. Am. Heart Assoc. 5, e003031.
Parhami, F., Morrow, A.D., Balucan, J., Leitinger, N., Watson, A.D., Tintut, Y., Berliner, J.A., and Demer, L.L. (1997). Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17, 680–687.
Patel (2013). Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality. J. Clin. Med. Res.
Paul, A., Calleja, L., Camps, J., Osada, J., Vilella, E., Ferré, N., Mayayo, E., and Joven, J. (2000). The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 68, 457–465.
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988). Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296, 313–316.
Pugliese, G., Iacobini, C., Blasetti Fantauzzi, C., and Menini, S. (2015). The dark and bright side of atherosclerotic calcification. Atherosclerosis 238, 220–230.
Rådmark, O., and Samuelsson, B. (2010). Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun. 396, 105–110.
Ramos, R., García-Gil, M., Comas-Cufí, M., Quesada, M., Marrugat, J., Elosua, R., Sala, J., Grau, M., Martí, R., Ponjoan, A., et al. (2016). Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. J. Am. Coll. Cardiol. 67, 630–640.
Rashid, S., Curtis, D.E., Garuti, R., Anderson, N.N., Bashmakov, Y., Ho, Y.K., Hammer, R.E., Moon, Y.-A., and Horton, J.D. (2005). Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. U. S. A. 102, 5374–5379.
Ravnskov, U. (2003). High cholesterol may protect against infections and atherosclerosis. QJM 96, 927–934.
Ridker, P.M., Cook, N.R., Lee, I.-M., Gordon, D., Gaziano, J.M., Manson, J.E., Hennekens, C.H., and Buring, J.E. (2005). A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N. Engl. J. Med. 352, 1293–1304.
Ridker, P.M., Howard, C.P., Walter, V., Everett, B., Libby, P., Hensen, J., Thuren, T., and CANTOS Pilot Investigative Group (2012). Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739–2748.
Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El Shahawy, M., et al. (2015). Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N. Engl. J. Med. 372, 1489–1499.
Rosenson, R.S., and Stafforini, D.M. (2012). Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res. 53, 1767–1782.
Rosman, Z., Shoenfeld, Y., and Zandman-Goddard, G. (2013). Biologic therapy for autoimmune diseases: an update. BMC Med. 11, 88.
Ross, R. (1999). Atherosclerosis--an inflammatory disease. N. Engl. J. Med. 340, 115–126.
Rudijanto, A. (2007). The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Medica Indones. 39, 86–93.
Ryan, C., Leonardi, C.L., Krueger, J.G., Kimball, A.B., Strober, B.E., Gordon, K.B., Langley, R.G., de Lemos, J.A., Daoud, Y., Blankenship, D., et al. (2011). Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306, 864–871.
Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001–1009.
Salvayre, R., Negre-Salvayre, null, and Camaré, C. (2015). Oxidative theory of atherosclerosis and antioxidants. Biochimie.
Seeger, F.H., Sedding, D., Langheinrich, A.C., Haendeler, J., Zeiher, A.M., and Dimmeler, S. (2010). Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res. Cardiol. 105, 389–397.
Shaposhnik, Z., Wang, X., Trias, J., Fraser, H., and Lusis, A.J. (2009). The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623–629.
Sheehan, A.L., Carrell, S., Johnson, B., Stanic, B., Banfi, B., and Miller, F.J. (2011). Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216, 321–326.
Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., and Packard, C.J. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301–1307.
Shiomi, M., Ito, T., Hirouchi, Y., and Enomoto, M. (2001). Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins. Ann. N. Y. Acad. Sci. 947, 419–423.
Smith, J.A.M. (2002). Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. Clin. Cardiol. 25, 91–94.
Sobey, C.G., Judkins, C.P., Rivera, J., Lewis, C.V., Diep, H., Lee, H.W., Kemp-Harper, B.K., Broughton, B.R.S., Selemidis, S., Gaspari, T.A., et al. (2015). NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis. Free Radic. Res. 49, 186–198.
Steering Committee of the Physicians’ Health Study Research Group* (1989). Final Report on the Aspirin Component of the Ongoing Physicians’ Health Study. N. Engl. J. Med. 321, 129–135.
Steinberg, D. (1995). Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet Lond. Engl. 346, 36–38.
Steinberg, D. (1997). A critical look at the evidence for the oxidation of LDL in atherogenesis. Atherosclerosis 131 Suppl, S5-7.
Strong, J.P., Malcom, G.T., Newman, W.P., and Oalmann, M.C. (1992). Early lesions of atherosclerosis in childhood and youth: natural history and risk factors. J. Am. Coll. Nutr. 11 Suppl, 51S–54S.
Suckling, K.E. (2009). Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin. Investig. Drugs 18, 1425–1430.
Sundell, C.L., Somers, P.K., Meng, C.Q., Hoong, L.K., Suen, K.-L., Hill, R.R., Landers, L.K., Chapman, A., Butteiger, D., Jones, M., et al. (2003). AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J. Pharmacol. Exp. Ther. 305, 1116–1123.
Tabas, I. (1999). Nonoxidative modifications of lipoproteins in atherogenesis. Annu. Rev. Nutr. 19, 123–139.
Takase, H., Hashimoto, A., Okutsu, R., Hirose, Y., Ito, H., Imaizumi, T., Miyakoda, G., and Mori, T. (2007). Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung. 57, 185–191.
Tardif, J.-C., McMurray, J.J.V., Klug, E., Small, R., Schumi, J., Choi, J., Cooper, J., Scott, R., Lewis, E.F., L’Allier, P.L., et al. (2008a). Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Lond. Engl. 371, 1761–1768.
Tardif, J.-C., Grégoire, J., L’Allier, P.L., Ibrahim, R., Anderson, T.J., Reeves, F., Title, L.M., Schampaert, E., LeMay, M., Lespérance, J., et al. (2008b). Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 197, 480–486.
Tardif, J.-C., L’allier, P.L., Ibrahim, R., Grégoire, J.C., Nozza, A., Cossette, M., Kouz, S., Lavoie, M.-A., Paquin, J., Brotz, T.M., et al. (2010). Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging 3, 298–307.
Tertov, V.V., Orekhov, A.N., and Smirnov, V.N. (1986). Agents that increase cellular cyclic AMP inhibit proliferative activity and decrease lipid content in cells cultured from atherosclerotic human aorta. Artery 13, 365–372.
Tintut, Y., Patel, J., Parhami, F., and Demer, L.L. (2000). Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102, 2636–2642.
Toyoda, K., Uchiyama, S., Hoshino, H., Kimura, K., Origasa, H., Naritomi, H., Minematsu, K., Yamaguchi, T., and CSPS.com Study Investigators (2015). Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int. J. Stroke Off. J. Int. Stroke Soc. 10, 253–258.
Tzellos, T., Kyrgidis, A., and Zouboulis, C.C. (2013). Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. JEADV 27, 622–627.
Vrecer, M., Turk, S., Drinovec, J., and Mrhar, A. (2003). Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int. J. Clin. Pharmacol. Ther. 41, 567–577.
Waksman, R., Ajani, A.E., Pichard, A.D., Torguson, R., Pinnow, E., Canos, D., Satler, L.F., Kent, K.M., Kuchulakanti, P., Pappas, C., et al. (2004). Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J. Am. Coll. Cardiol. 44, 1386–1392.
Wang, W., Zhang, J., Wu, W., Li, J., Ma, Y., Chen, W., Yan, H., Wang, K., Xu, W., Shen, J., et al. (2011). Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PloS One 6, e23425.
Wei, L. (2005). Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 330, 821–0.
Wei, L., Ebrahim, S., Bartlett, C., Davey, P.D., Sullivan, F.M., and MacDonald, T.M. (2005). Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 330, 821.
Weinbaum, S., Tarbell, J.M., and Damiano, E.R. (2007). The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 9, 121–167.
Westlake, S.L., Colebatch, A.N., Baird, J., Kiely, P., Quinn, M., Choy, E., Ostor, A.J.K., and Edwards, C.J. (2010). The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49, 295–307.
Willette, R.N., Eybye, M.E., Olzinski, A.R., Behm, D.J., Aiyar, N., Maniscalco, K., Bentley, R.G., Coatney, R.W., Zhao, S., Westfall, T.D., et al. (2009). Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J. Pharmacol. Exp. Ther. 330, 964–970.
Williams, J.K., Armstrong, M.L., and Heistad, D.D. (1988). Vasa vasorum in atherosclerotic coronary arteries: responses to vasoactive stimuli and regression of atherosclerosis. Circ. Res. 62, 515–523.
Winnik, S., Lohmann, C., Siciliani, G., von Lukowicz, T., Kuschnerus, K., Kraenkel, N., Brokopp, C.E., Enseleit, F., Michels, S., Ruschitzka, F., et al. (2013). Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. Int. J. Cardiol. 168, 2453–2461.
Wójcicki, J., Hinek, A., Jaworska, M., and Samochowiec, L. (1986). The effect of colchicine on the development of experimental atherosclerosis in rabbits. Pol. J. Pharmacol. Pharm. 38, 343–348.
Wu, C.H., Chi, J.C., Jerng, J.S., Lin, S.J., Jan, K.M., Wang, D.L., and Chien, S. (1990). Transendothelial macromolecular transport in the aorta of spontaneously hypertensive rats. Hypertension 16, 154–161.
Yamagishi, S., Nakamura, K., Matsui, T., Sato, T., and Takeuchi, M. (2006). Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med. Hypotheses 66, 844–846.
Zhang, J., Dierckx, R., and Cleland, J.G. (2014). Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 32, 57–58.
Ziqiang, X., Jingjun, W., Jianjian, Z., Yong, L., and Peng, X. (2015). Tadalafil attenuates graft arteriosclerosis of aortic transplant in a rat model. Iran. J. Basic Med. Sci. 18, 927–931.

Наиболее читаемые статьи этого автора (авторов)